John  Dasher,Lavanya  Kondapalli,Carrie Lenneman,
Immune Checkpoint Myocarditis from Adjuvant Treatment of Melanoma
Global Clinical Case Reports
2020

http://dx.doi.org/10.31487/j.GCCR.2020.01.05
https://www.sciencerepository.org/immune-checkpoint-myocarditis-from-adjuvant-treatment-of-melanoma_GCCR-2020-1-105 
Abstract: Immune checkpoint inhibitors (ICIs) are effective therapy for many metastatic cancers and are now being
used as adjuvant treatment for many stage III cancers to reduce the high risk of reoccurrence. ICIs activate
a patient’s own T-cells to fight cancer, but in some cases, immune-related adverse events (irAEs) with
inflammation of many organs can occur. Rare cases of myocarditis have been reported. More data is needed
to improve our ability to monitor, diagnose and treat irAEs.
Keywords: Immunotherapy, myocarditis, immune-related adverse events, cardiotoxicity